BIOMEDICINE
The National Reimbursement Drug List (NRDL) is the main public reimbursement mechanism in China, covering 98% of the entire population. China released its annual update of the NRDL list on December 3, 2021, which was implemented from January 1, 2022. A total of 74 drugs were added to the NRDL list and 11 were removed from it. 91% of the added drugs are new therapies reimbursed for the first time in China.
